GH Research PLC (NASDAQ:GHRS - Free Report) - Research analysts at HC Wainwright issued their FY2029 earnings per share estimates for GH Research in a report issued on Monday, January 27th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of $0.10 for the year. HC Wainwright has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.80) per share.
Separately, Canaccord Genuity Group cut their price target on GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a report on Monday, November 18th.
View Our Latest Stock Report on GHRS
GH Research Stock Up 9.4 %
Shares of NASDAQ GHRS traded up $0.91 during midday trading on Tuesday, hitting $10.60. 122,799 shares of the company's stock were exchanged, compared to its average volume of 98,437. The firm has a market capitalization of $551.50 million, a PE ratio of -13.42 and a beta of 0.84. GH Research has a 12 month low of $6.00 and a 12 month high of $14.99. The company's 50 day moving average price is $8.38 and its 200 day moving average price is $8.93.
Institutional Investors Weigh In On GH Research
A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. lifted its stake in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,686,689 shares of the company's stock after buying an additional 85,000 shares during the period. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. Institutional investors own 56.90% of the company's stock.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Read More
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
